BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 20653783)

  • 1. Pulmonary adenocarcinoma with microcystic histology and intratumoral heterogeneity of EGFR gene polymorphism.
    Yeh YC; Chou TY
    Histopathology; 2010 Jul; 57(1):112-20. PubMed ID: 20653783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expressional and mutational analysis of PHLDA3 gene in common human cancers.
    Yoo NJ; Kim YR; Lee SH
    Pathology; 2011 Aug; 43(5):510-1. PubMed ID: 21753719
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR/KRAS/p53 mutations in lung adenocarcinoma.
    Iwakawa R; Kohno T; Anami Y; Noguchi M; Suzuki K; Matsuno Y; Mishima K; Nishikawa R; Tashiro F; Yokota J
    Clin Cancer Res; 2008 Jun; 14(12):3746-53. PubMed ID: 18559592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
    Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
    Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.
    Kosaka T; Yatabe Y; Endoh H; Kuwano H; Takahashi T; Mitsudomi T
    Cancer Res; 2004 Dec; 64(24):8919-23. PubMed ID: 15604253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
    Willmore-Payne C; Holden JA; Layfield LJ
    Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between EGFR gene mutation pattern and Akt phosphorylation in pulmonary adenocarcinomas.
    Ikeda S; Takabe K; Inagaki M; Funakoshi N; Suzuki K; Shibata T
    Pathol Int; 2007 May; 57(5):268-75. PubMed ID: 17493174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis.
    Sartori G; Cavazza A; Bertolini F; Longo L; Marchioni A; Costantini M; Barbieri F; Migaldi M; Rossi G
    Am J Clin Pathol; 2008 Feb; 129(2):202-10. PubMed ID: 18208799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-grade fetal adenocarcinoma of the lung is a tumour with a fetal phenotype that shows diverse differentiation, including high-grade neuroendocrine carcinoma: a clinicopathological, immunohistochemical and mutational study of 20 cases.
    Suzuki M; Yazawa T; Ota S; Morimoto J; Yoshino I; Yamanaka S; Inayama Y; Kawabata Y; Shimizu Y; Komatsu M; Notohara K; Koda K; Nakatani Y
    Histopathology; 2015 Dec; 67(6):806-16. PubMed ID: 25851923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant nuclear localization and gene mutation of beta-catenin in low-grade adenocarcinoma of fetal lung type: up-regulation of the Wnt signaling pathway may be a common denominator for the development of tumors that form morules.
    Nakatani Y; Masudo K; Miyagi Y; Inayama Y; Kawano N; Tanaka Y; Kato K; Ito T; Kitamura H; Nagashima Y; Yamanaka S; Nakamura N; Sano J; Ogawa N; Ishiwa N; Notohara K; Resl M; Mark EJ
    Mod Pathol; 2002 Jun; 15(6):617-24. PubMed ID: 12065775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling.
    Conde E; Angulo B; Tang M; Morente M; Torres-Lanzas J; Lopez-Encuentra A; Lopez-Rios F; Sanchez-Cespedes M
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):710-7. PubMed ID: 16467080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.
    Wu CC; Hsu HY; Liu HP; Chang JW; Chen YT; Hsieh WY; Hsieh JJ; Hsieh MS; Chen YR; Huang SF
    Cancer; 2008 Dec; 113(11):3199-208. PubMed ID: 18932251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinoma.
    Koga T; Hashimoto S; Sugio K; Yoshino I; Mojtahedzadeh S; Matsuo Y; Yonemitsu Y; Sugimachi K; Sueishi K
    Clin Cancer Res; 2001 Jun; 7(6):1730-8. PubMed ID: 11410513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-catenin mutations in pulmonary blastomas: association with morule formation.
    Sekine S; Shibata T; Matsuno Y; Maeshima A; Ishii G; Sakamoto M; Hirohashi S
    J Pathol; 2003 Jun; 200(2):214-21. PubMed ID: 12754743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer.
    Suzuki M; Shigematsu H; Iizasa T; Hiroshima K; Nakatani Y; Minna JD; Gazdar AF; Fujisawa T
    Cancer; 2006 May; 106(10):2200-7. PubMed ID: 16598760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.
    Kern JA; Slebos RJ; Top B; Rodenhuis S; Lager D; Robinson RA; Weiner D; Schwartz DA
    J Clin Invest; 1994 Feb; 93(2):516-20. PubMed ID: 7906694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive advantage of a cell type classification for pulmonary adenocarcinoma coupled with data for p53, K-ras and EGFR alterations.
    Okada A; Shimmyo T; Hashimoto T; Kobayashi Y; Miyagi Y; Ishikawa Y; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Sci; 2010 Jul; 101(7):1745-53. PubMed ID: 20491778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations.
    Sakuma Y; Matsukuma S; Yoshihara M; Nakamura Y; Noda K; Nakayama H; Kameda Y; Tsuchiya E; Miyagi Y
    Am J Clin Pathol; 2007 Jul; 128(1):100-8. PubMed ID: 17580276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor mutations in small cell lung cancer.
    Tatematsu A; Shimizu J; Murakami Y; Horio Y; Nakamura S; Hida T; Mitsudomi T; Yatabe Y
    Clin Cancer Res; 2008 Oct; 14(19):6092-6. PubMed ID: 18829487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.